YAP/TEAD Pathway Modulators for Neurodegeneration

YAP/TEAD Pathway Modulators for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">YAP/TEAD Pathway Modulators for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Anti-aggregation therapy</td>
<td>Synergistic with protein clearance</td>
</tr>
<tr>
<td class="label">Antioxidants</td>
<td>Complement oxidative stress response</td>
</tr>
<tr>
<td class="label">Neurotrophic factors</td>
<td>Support neuronal survival</td>
</tr>
<tr>
<td class="label">Anti-inflammatory agents</td>
<td>Target neuroinflammation</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Verteporfin</td>
<td>Various (repurposing)</td>
</tr>
<tr>
<td class="label">TT-10</td>
<td>Academic/Industry</td>
</tr>
<tr>
<td class="label">CA3</td>
<td>Research</td>
</tr>
</table>

The [YAP/TEAD Hippo signaling pathway](/mechanisms/yap-taz-hippo-signaling-neurodegeneration) has emerged as a compelling therapeutic target for neurodegenerative diseases. Yes-associated protein (YAP) and its paralog TAZ (WWTR1) are transcriptional coactivators that regulate cell survival, neurogenesis, and cellular stress responses. In neurodegeneration, YAP/TAZ activity is suppressed by amyloid-beta, tau pathology, and alpha-synuclein aggregation, contributing to neuronal death.

YAP/TEAD Pathway Modulators for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">YAP/TEAD Pathway Modulators for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Anti-aggregation therapy</td>
<td>Synergistic with protein clearance</td>
</tr>
<tr>
<td class="label">Antioxidants</td>
<td>Complement oxidative stress response</td>
</tr>
<tr>
<td class="label">Neurotrophic factors</td>
<td>Support neuronal survival</td>
</tr>
<tr>
<td class="label">Anti-inflammatory agents</td>
<td>Target neuroinflammation</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Verteporfin</td>
<td>Various (repurposing)</td>
</tr>
<tr>
<td class="label">TT-10</td>
<td>Academic/Industry</td>
</tr>
<tr>
<td class="label">CA3</td>
<td>Research</td>
</tr>
</table>

The [YAP/TEAD Hippo signaling pathway](/mechanisms/yap-taz-hippo-signaling-neurodegeneration) has emerged as a compelling therapeutic target for neurodegenerative diseases. Yes-associated protein (YAP) and its paralog TAZ (WWTR1) are transcriptional coactivators that regulate cell survival, neurogenesis, and cellular stress responses. In neurodegeneration, YAP/TAZ activity is suppressed by amyloid-beta, tau pathology, and alpha-synuclein aggregation, contributing to neuronal death.

YAP/TEAD pathway modulators aim to restore YAP nuclear activity and promote neuroprotection through multiple mechanisms. This page covers the scientific rationale, drug candidates, and clinical development status for this emerging therapeutic approach.

Scientific Rationale

YAP/TAZ Dysregulation in Neurodegeneration

In Alzheimer's disease and Parkinson's disease, YAP/TAZ activity is suppressed through multiple mechanisms:

Alzheimer's Disease:

• Amyloid-beta reduces YAP nuclear localization in neurons
• Hyperphosphorylated tau sequesters YAP in the cytoplasm
• Age-related decline in Hippo pathway activity correlates with reduced neurogenesis

• Alpha-synuclein aggregation suppresses YAP/TAZ activity
• Mitochondrial toxins reduce YAP nuclear localization
• YAP is particularly important for dopaminergic neuron survival

Neuroprotective Functions of YAP

YAP activation promotes multiple protective functions:

Therapeutic Window

The challenge in targeting YAP/TEAD is achieving neuroprotection without promoting oncogenic effects. YAP's role in cell proliferation makes complete pathway activation potentially risky. However, selective neuronal activation or cell-type specific targeting may provide therapeutic benefit while minimizing cancer risk.

Drug Candidates

Verteporfin

Mechanism: Verteporfin is an FDA-approved photosensitizer for photodynamic therapy that has been found to activate YAP by inhibiting its interaction with LATS1/2 kinases. It promotes YAP nuclear translocation and transcriptional activity.

Preclinical Evidence:

• Reduces neuronal apoptosis in amyloid-beta toxicity models
• Protects against oxidative stress in neuronal cultures
• Promotes neurogenesis in hippocampal progenitor cells

Challenges:

• Phototoxicity concerns with systemic administration
• Limited understanding of dosing for neuroprotection
• Need for brain-penetrant formulations

TT-10

Mechanism: TT-10 is a small molecule YAP activator that promotes YAP nuclear localization and transcriptional activity without significant phototoxicity.

Preclinical Evidence:

• Neuroprotection in MPTP Parkinson's disease model
• Reduced dopaminergic neuron loss
• Improved motor function in animal studies

Advantages:

• Designed specifically for YAP activation
• Better safety profile than verteporfin
• Potential for oral administration

CA3 (TEAD Inhibitor)

Mechanism: CA3 is a TEAD family inhibitor that blocks YAP-TEAD transcriptional activity. While this may seem counterintuitive, in certain disease contexts reducing pro-inflammatory TEAD activity in glial cells while sparing neuronal YAP may be beneficial.

Rationale: YAP has context-dependent effects—protective in neurons but pro-inflammatory in microglia. Selective TEAD inhibition may reduce neuroinflammation without affecting neuronal YAP.

Preclinical Evidence:

• Reduced microglial activation in models
• Decreased pro-inflammatory cytokine production
• Protection of neurons from glial-mediated toxicity

• Achieving cell-type selectivity
• Balancing inflammatory vs. protective effects
• Understanding optimal inhibition level

Mechanism of Action

Therapeutic Applications

Alzheimer's Disease

YAP/TAZ modulators address multiple aspects of AD pathophysiology:

• Amyloid toxicity: Restore YAP activity suppressed by Aβ
• Tau pathology: Prevent YAP sequestration by phosphorylated tau
• Neurogenesis: Support hippocampal neurogenesis
• Oxidative stress: Enhance antioxidant response

Parkinson's Disease

In PD, YAP/TAZ modulators target:

• Dopaminergic neuron survival: Protect vulnerable SNpc neurons
• Alpha-synuclein toxicity: Restore activity suppressed by aggregation
• Mitochondrial dysfunction: Leverage AMPK-YAP connection
• Neuroinflammation: Modulate microglial activation

Other Disorders

• Amyotrophic lateral sclerosis (ALS): Support motor neuron survival
• Huntington's disease: Address polyglutamine toxicity
• Multiple system atrophy: Target oligodendrocyte dysfunction

Combination Strategies

YAP/TEAD modulators may be combined with:

Challenges and Future Directions

Key Challenges

Emerging Approaches

• Phosphodiesterase inhibitors: Some PDEs affect YAP activity
• Mechanical stimulation: Exercise and vibration may activate pathway
• Gene therapy: AAV-mediated YAP delivery
• Protein-protein interaction disrupters: Novel small molecules

Clinical Development Status

Cross-Linking to Related Pages

• [YAP/TAZ (Hippo) Signaling in Neurodegeneration](/mechanisms/yap-taz-hippo-signaling-neurodegeneration)
• [Hippo Pathway in Parkinson's Disease](/mechanisms/hippo-signaling-parkinsons-disease)
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Neuroinflammation](/mechanisms/neuroinflammation-alzheimers)
• [YAP1 Gene](/genes/yap1)
• [TEAD1 Gene](/genes/tead1)
• [WWTR1 (TAZ) Gene](/genes/wwtr1)

Conclusion

YAP/TEAD pathway modulators represent a promising therapeutic approach for neurodegenerative diseases. By restoring YAP activity suppressed by disease pathology, these compounds may provide neuroprotection through multiple mechanisms. While significant challenges remain—particularly regarding CNS penetration and safety—the strong mechanistic rationale and growing preclinical evidence support continued development.

The dual role of YAP in both neuronal survival and neuroinflammation adds complexity but also provides opportunities for selective targeting. Future work should focus on developing brain-penetrant compounds, achieving cell-type specificity, and identifying biomarkers for patient selection.

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;